Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: ng/L
حداقل ۵ — حداکثر ۱۵۰ • واحد: ml/min
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage I1–1
- Stage II2–2
- Stage III3–3
The Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include nt probnp. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Staging system for transthyretin amyloid cardiomyopathy using NT-proBNP and estimated glomerular filtration rate (eGFR) to stratify patients into prognostic categories for both wild-type and variant ATTR-CM
Clinical Indication
The Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is indicated for bedside clinical practice to support Staging system for transthyretin amyloid cardiomyopathy using NT-proBNP and estimated glomerular filtration rate (eGFR) to stratify patients into prognostic categories for both wild-type and variant ATTR-CM. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Regular monitoring of biomarkers recommended for disease progression assessment.
Stage I: NT-proBNP ≤3000 ng/L AND eGFR ≥45 ml/min; Stage III: NT-proBNP >3000 ng/L AND eGFR <45 ml/min; Stage II: All other combinations
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| nt_probnp | float | Yes | N-terminal pro-B-type natriuretic peptide (NT-proBNP) level(ng/L) |
| egfr | float | Yes | Estimated glomerular filtration rate (eGFR)(ml/min) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Stage I | Best prognosis |
| 2–2 | Stage II | Intermediate prognosis |
| 3–3 | Stage III | Worst prognosis |
Evidence-Based References (EBM)
- Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.DOI: 10.1093/eurheartj/ehx589
- Fontana M, Corovic A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2345-2356. doi: 10.1016/j.jcmg.2019.06.023.DOI: 10.1016/j.jcmg.2019.06.023
- Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033.DOI: 10.1016/j.jacc.2016.06.033